MARKET

SRTS

SRTS

Sensus Hlthcr
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.690
-0.270
-6.82%
Closed 16:00 09/27 EDT
OPEN
4.000
PREV CLOSE
3.960
HIGH
4.000
LOW
3.650
VOLUME
50.01K
TURNOVER
--
52 WEEK HIGH
6.09
52 WEEK LOW
2.320
MARKET CAP
61.33M
P/E (TTM)
-29.3790
1D
5D
1M
3M
1Y
5Y
Sensus Healthcare to Participate at H.C. Wainwright 23rd Annual Global Investment Conference
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announced that Joe Sardano, chairman and chief...
GlobeNewswire · 09/08 13:00
Return on Capital Employed Insights for Sensus Healthcare
According to Benzinga Pro data, during Q2, Sensus Healthcare (NASDAQ:SRTS) posted sales of $5.42 million. Earnings were up 74.98%, but Sensus Healthcare still reported an overall loss of $279.00 thousand.
Benzinga · 09/02 15:33
55 Stocks Moving In Friday's Mid-Day Session
Gainers
Benzinga · 08/06 16:00
Sensus Healthcare, Inc. (SRTS) Reports Q2 Loss, Tops Revenue Estimates
Sensus Healthcare, Inc. (SRTS) delivered earnings and revenue surprises of 60.00% and 33.12%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/06 00:15
BRIEF-Sensus Healthcare Q2 Revenue Rose 358 Percent To $5.4 Million
reuters.com · 08/05 22:02
Sensus Healthcare EPS beats by $0.04, beats on revenue
Sensus Healthcare (NASDAQ:SRTS): Q2 GAAP EPS of -$0.02 beats by $0.04. Revenue of $5.4M (+357.6% Y/Y) beats by $1.12M. Press Release
Seekingalpha · 08/05 20:37
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers
Benzinga · 08/05 20:31
Sensus Healthcare Reports Second Quarter 2021 Financial Results
Revenues of $5.4 million up 358% year-over-year, up 77% sequentially Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in...
GlobeNewswire · 08/05 20:05
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SRTS. Analyze the recent business situations of Sensus Hlthcr through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average SRTS stock price target is 7.04 with a high estimate of 7.75 and a low estimate of 6.00.
High7.75
Average7.04
Low6.00
Current 3.690
EPS
Actual
Estimate
-0.10-0.05-0.010.03
Q3 2020
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Institutional Holdings
Institutions: 29
Institutional Holdings: 1.62M
% Owned: 9.74%
Shares Outstanding: 16.62M
TypeInstitutionsShares
Increased
7
23.62K
New
1
3.00K
Decreased
6
64.71K
Sold Out
3
35.26K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
-2.19%
Healthcare Equipment & Supplies
-1.88%
Key Executives
Chairman/President/Chief Executive Officer/Co-Founder/Director
Joseph Sardano
Co-Founder/Executive Vice President
Stephen Cohen
Chief Financial Officer
Javier Rampolla
Chief Operating Officer
Nicolas Soro
Chief Technology Officer
Yonatan Vainer
Vice President/General Counsel
Michael Sardano
Director
Megan Cornish
Non-Executive Director
Anthony Petrelli
Non-Executive Independent Director
John Heinrich
Non-Executive Independent Director
William McCall
Non-Executive Independent Director
Samuel O'Rear
No Data
About SRTS
Sensus Healthcare, Inc. is a medical device company. The Company is focused on providing non-invasive treatments for both oncological and non-oncological skin conditions. The Company uses a low-energy X-ray technology known as superficial radiation therapy (SRT). The Company incorporated SRT into its portfolio of treatment devices: the SRT-100, SRT-100 Plus and SRT-100 Vision. The Company's product, SRT-100, is a photon x-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its other two products, such as SRT-100 Plus and SRT-100 Vision provides customers with additional options compared to the SRT-100 base model.

Webull offers kinds of Sensus Healthcare Inc stock information, including NASDAQ:SRTS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SRTS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SRTS stock methods without spending real money on the virtual paper trading platform.